

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 December 2022 (22.12.2022)



(10) International Publication Number
WO 2022/266236 A1

(51) International Patent Classification:

A61K 31/4375 (2006.01) C07D 413/14 (2006.01)
A61K 31/444 (2006.01) C07D 471/04 (2006.01)
A61K 31/5025 (2006.01) C07D 487/04 (2006.01)
A61K 31/519 (2006.01) C07D 487/10 (2006.01)
A61K 31/53 (2006.01) C07D 491/048 (2006.01)
A61P 31/20 (2006.01) C07D 498/10 (2006.01)
C07D 401/12 (2006.01) C07D 519/00 (2006.01)
C07D 401/14 (2006.01) A61P 31/14 (2006.01)
C07D 403/12 (2006.01) A61P 35/00 (2006.01)
C07D 405/14 (2006.01)

(21) International Application Number:

PCT/US2022/033653

(22) International Filing Date:

15 June 2022 (15.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/212,388 18 June 2021 (18.06.2021) US
63/263,427 02 November 2021 (02.11.2021) US
63/363,777 28 April 2022 (28.04.2022) US

(71) Applicant: **ALIGOS THERAPEUTICS, INC.** [US/US];
1 Corporate Drive, 2nd Floor, South San Francisco, California 94080 (US).


(72) Inventors: **WU, Tongfei**; c/o Aligos Therapeutics, Inc., 1 Corporate Drive, 2nd Floor, South San Francisco, California 94080 (US). **RABOISSON, Pierre Jean-Marie Bernard**; c/o Aligos Therapeutics, Inc., 1 Corporate Drive, 2nd Floor, South San Francisco, California 94080 (US). **GONZALEZ, Francois**; c/o Aligos Therapeutics, Inc., 1 Corporate Drive, 2nd Floor, South San Francisco, California 94080 (US). **STOYCHEVA, Antitsa Dimitrova**; c/o Aligos Therapeutics, Inc., 1 Corporate Drive, 2nd Floor, South San Francisco, California 94080 (US). **LIU, Cheng**; c/o Aligos Therapeutics, Inc., 1 Corporate Drive, 2nd Floor, South San Francisco, California 94080 (US). **DEVAL, Jerome**; c/o Aligos Therapeutics, Inc., 1 Corporate Drive, 2nd Floor, South San Francisco, California 94080 (US). **MCGOWAN, David**; c/o Aligos Therapeutics, Inc., 1 Corporate Drive, 2nd Floor, South San Francisco, California 94080 (US).

(74) Agent: **MILLER, Kimberly J.**; Knobbe Martens Olson & Bear LLP, 2040 Main Street, Fourteenth Floor, Irvine, California 92614 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

(54) Title: METHODS AND COMPOSITIONS FOR TARGETING PD-L1

Figure 1



(57) Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.

WO 2022/266236 A1

[Continued on next page]

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*